Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Columbia University researchers testing opioid use disorder vaccine

Thousands of people die each year because of an opioid-related overdose, and the coronavirus pandemic only fueled that fire, contributing to a record level of deaths in 2020.

Medications exist that can help treat opioid use disorders, but about half of those who take them end up relapsing after about six months. Now, researchers at Columbia University in New York are developing a vaccine they hope could prevent opioid overdose deaths by blocking the drugs’ ability to reach the brain.

The team is enrolling up to 24 volunteers who are active opioid users but are not taking medications to treat their disorder in an early clinical trial designed to determine if the vaccine is “well tolerated and safe.” Researchers will also study whether the shot triggers the production of sufficient antibodies that could prevent the drug from seeping into the brain.

If the vaccine proves safe, then the team will add another 21 participants. It’s the first experimental vaccine designed for the treatment of opioid use disorder to be tested in the U.S.

Source: EMS 1

https://www.ems1.com/opioids/articles/columbia-university-researchers-testing-opioid-use-disorder-vaccine-Nz4jddn9YJMewljl/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!